Jianyou Co., Ltd. announced that Meitheal Pharmaceuticals Inc., a subsidiary of the company, recently received approval from the US FDA to increase the production site for amikacin sulfate injection and approved production at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. site. This product is used to treat serious infections caused by sensitive gram-negative bacteria in the short term. This approval further enriches the company's international product pipeline and strengthens the international market layout. If it is promoted for sale in the US market in the future, it is expected to have a positive impact on the company's business performance. Up to now, the company has invested about 4.09 million yuan in R&D expenses on this project.

Zhitongcaijing · 1d ago
Jianyou Co., Ltd. announced that Meitheal Pharmaceuticals Inc., a subsidiary of the company, recently received approval from the US FDA to increase the production site for amikacin sulfate injection and approved production at the Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. site. This product is used to treat serious infections caused by sensitive gram-negative bacteria in the short term. This approval further enriches the company's international product pipeline and strengthens the international market layout. If it is promoted for sale in the US market in the future, it is expected to have a positive impact on the company's business performance. Up to now, the company has invested about 4.09 million yuan in R&D expenses on this project.